Christine Fletcher
Every week, we talk about important data and analytics topics with data science leaders from around the world on Facebook Live. You can subscribe to the DataTalk podcast on iTunes, Google Play, Stitcher, SoundCloud, and Spotify.
DataTalk features data science leaders at MIT, Caltech, United Nations, Gartner, Twitter, Salesforce, Amazon, Oracle, IBM, Google, Spotify, Dow Jones and dozens of other startups and top data companies.
In this week’s #DataTalk, we chat with Christine Fletcher, Vice President of Biostatistics at GSK.
About Christine Fletcher
Chrissie is an Executive Director Biostatistics in Global Biostatistical Science (GBS) at Amgen. She is the GBS Therapeutic Area Head for Cardiovascular, Metabolic, Neuroscience, Nephrology and Inflammation therapeutic areas, and the EU Regional Head for GBS.
Chrissie also leads a Health Technology Assessment (HTA) Biostatistics group. Chrissie has worked in the Pharmaceutical Industry for 28 years and has experience of developing and commercialising new medicines in a variety of therapeutic areas across all phases of clinical development.
Chrissie is actively engaged in Statistical societies, Pharmaceutical trade associations and initiatives relating to the Pharmaceutical Industry. Chrissie is the Communications Officer, Chair of the HTA Special Interest Group (SIG) and member of the Regulatory Committee and Data Transparency SIG in EFSPI.
Chrissie is one of the Vice-Chairs of the Clinical Research Expert Group and is leading a sub-team focussed on Complex Trial Design in EFPIA. Chrissie is the lead EFPIA representative for the ICH E9(R1) Working Group, and she is leading an EFPIA/EFSPI ICH E9(R1) implementation working group. Chrissie is co-leading Taskforce 2 in the IMI ‘The GetReal Initiative’.
Chrissie is a Chartered Statistician of the Royal Statistical Society (RSS). Chrissie has an MSc in Applied Statistics and a BSc (Hons) in Statistics with Management Science Techniques.